Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    -0.10 (-0.38%)
Bid:
26.50
Ask:
26.90
Spread: 0.40 (1.509%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Dividend Timetable

20 Sep 2022 07:01

RNS Number : 9264Z
EKF Diagnostics Holdings PLC
20 September 2022
 

EKF Diagnostics Holdings plc

("EKF", the "Company" or the "Group")

 

Dividend Timetable

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, confirms that, further to the passing of the resolution at the AGM, a cash dividend of 1.2p per ordinary share will be paid in relation to its 2021 results as per the below timetable. The dividend will be paid to shareholders, on the register at close of business on 4 November 2022, on 1 December 2022.

 

The dividend timetable dates are detailed below:

 

Ex-dividend date:

3 November 2022

Record date:

4 November 2022

Payment date:

1 December 2022

 

 

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Mike Salter, CEO / Marc Davies, CFO

 Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Oliver Platts

Investec Bank plc (Joint Broker)

Tel: +44 (0)20 7597 4000

Gary Clarence / Daniel Adams / Ben Farrow

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Lianne Applegarth

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:

 

Point-of-Care

Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.

 

Central Laboratory

Clinical chemistry, Small lab analysers, Centrifuges

Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin

 

Life Sciences

Enzyme fermentation, Custom products and Bulk fermentation

 

Contract Manufacturing

Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits

 

Laboratory Testing

Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCGPUCPBUPPGQB
Date   Source Headline
20th Jun 201111:37 amRNSHolding(s) in Company
20th Jun 201111:35 amRNSHolding(s) in Company
17th Jun 20114:00 pmRNSHolding(s) in Company
16th Jun 20113:59 pmRNSHolding(s) in Company
15th Jun 20119:51 amRNSResults of General Meeting
13th Jun 20117:00 amRNSAnnual Financial Report
23rd May 20117:00 amRNSFinal Results
23rd May 20117:00 amRNSExclusive distribution agreement with Alere
23rd May 20117:00 amRNSProposed Acquisition and Placing
9th May 20114:40 pmRNSSecond Price Monitoring Extn
9th May 20114:35 pmRNSPrice Monitoring Extension
10th Mar 20118:17 amRNSIssue of Equity following Exercise of Options
27th Jan 20117:00 amRNSSFDA approval for Quo-Test in China
26th Jan 20118:49 amPRNCompletion of Sale of Admiral trademarks in Europe
21st Jan 20119:35 amPRNCompletion of Sale of Admiral trademarks in the Americas
14th Jan 20119:44 amRNSCompletion of Sale of trademarks in UK & Ireland
24th Dec 20107:00 amRNSDisposal of Admiral Sportswear Brand
9th Dec 201010:06 amRNSHolding(s) in Company
2nd Dec 20107:00 amRNSAcquisition
5th Nov 201012:22 pmRNSDeed of Variation
6th Oct 20103:03 pmRNSHolding(s) in Company
4th Oct 20108:41 amRNSCompletion of Acquisition
1st Oct 20107:00 amRNSAcquisition - SPA signed
28th Sep 201011:06 amRNSHolding(s) in Company
24th Sep 201012:00 pmRNSSenior Executive Incentive Package
24th Sep 20107:00 amRNSContract win & new distributor
23rd Sep 20107:00 amRNSAcquisition
14th Sep 20107:00 amRNSHalf Yearly Report
30th Jul 20107:00 amRNSTotal Voting Rights
27th Jul 20107:00 amRNSDirectorate Change
21st Jul 20107:00 amRNSSale of the Admiral sports rights
19th Jul 20103:01 pmRNSHolding(s) in Company
9th Jul 20109:32 amRNSHolding(s) in Company
9th Jul 20108:24 amRNSHolding(s) in Company
2nd Jul 201012:16 pmRNSResult of General Meeting
2nd Jul 201012:15 pmRNSResult of AGM
18th Jun 20103:03 pmRNSSchedule 1 - International Brand Licensing plc
15th Jun 20107:00 amRNSAcquisition and Placing
10th Jun 20107:00 amRNSFinal Results
28th May 20107:00 amRNSSale of Admiral trademarks
29th Apr 20107:00 amRNSAppointment of Adviser
5th Jan 201011:30 amRNSDisposal
4th Jan 20101:44 pmRNSResult of General Meeting
11th Dec 20097:00 amRNSIssue of Circular and Option Arrangements
26th Nov 20097:00 amRNSBoard Changes, New Strategy, Disposal and Placing
14th Sep 20097:00 amRNSInterim Results
17th Aug 200911:41 amRNSSale of Admiral Trademarks
30th Jun 200911:23 amRNSResult of AGM
20th May 20097:00 amRNSFinal Results
27th Apr 20097:00 amRNSNew Partnership

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.